<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342364</url>
  </required_header>
  <id_info>
    <org_study_id>RMA-2020-02</org_study_id>
    <nct_id>NCT04342364</nct_id>
  </id_info>
  <brief_title>Oocyte Survival After Vitrification With Slush Nitrogen Compared With Liquid Nitrogen</brief_title>
  <official_title>Oocyte Survival After Vitrification With Slush Nitrogen Compared With Liquid Nitrogen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reproductive Medicine Associates of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reproductive Medicine Associates of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the use of slush nitrogen results in higher&#xD;
      post-thaw survival rates for oocytes compared to conventionally used liquid nitrogen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, controlled trial which seeks to characterize oocyte survival rate&#xD;
      following vitrification and subsequent warming with both slush nitrogen and liquid nitrogen.&#xD;
      After warming, fertilization and embryology outcomes will be assessed.&#xD;
&#xD;
      Oocyte donors and a single donor sperm source will be utilized. Following enrollment, oocyte&#xD;
      donors will undergo ovarian stimulation and oocyte retrieval. The mature (MII) oocytes&#xD;
      obtained for each patient will then be assigned a number and randomized via block&#xD;
      randomization to one of two treatment groups (liquid nitogen or slush nitrogen). Through&#xD;
      block randomization, this will create a paired population of oocytes so that half of each&#xD;
      patient's oocytes will undergo cryopreservation with liquid nitrogen and half will undergo&#xD;
      cryopreservation with slush nitrogen. Timing of hyaluronidase stripping and vitrification&#xD;
      will be consistent with current institutional clinical practice for oocytes.&#xD;
&#xD;
      Following cryopreservation, oocytes will be warmed and intracytoplasmic sperm injection will&#xD;
      be performed and subsequent embryology outcomes tracked.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 8, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">May 11, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Trial in a paired design</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>embryologist assessing oocyte survival (primary outcome) is blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>oocyte survival rate</measure>
    <time_frame>within 5 minutes post warming</time_frame>
    <description>number of viable oocytes post warming</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fertilization rate</measure>
    <time_frame>18 hours post injection</time_frame>
    <description>number of zygotes post intracytoplasmic sperm injection procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blastulation rate</measure>
    <time_frame>4-6 days after fertilization</time_frame>
    <description>number of zygotes reaching the blastocyst stage of embryo development</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>euploid rate</measure>
    <time_frame>1 week after trophectoderm biopsy</time_frame>
    <description>number of chromosomally normal embryos</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Slush nitrogen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oocytes are randomized to undergo vitrification utilizing slush nitrogen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liquid Nitrogen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oocytes are randomized to undergo vitrification utilizing liquid nitrogen which is the current standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vitrification via slush nitrogen</intervention_name>
    <description>oocytes will be vitrified using slush nitrogen</description>
    <arm_group_label>Slush nitrogen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vitrification via liquid nitrogen</intervention_name>
    <description>oocytes will be vitrified using liquid nitrogen which is currently routine practice</description>
    <arm_group_label>Liquid Nitrogen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria for oocyte donors:&#xD;
&#xD;
          1. Age 30 years or younger who meet institutional criteria to be an oocyte donor.&#xD;
&#xD;
          2. Patients who agree to donate oocytes for research purposes and agree to the study&#xD;
             protocol.&#xD;
&#xD;
          3. The subgroup of oocyte donors age 35-38 will not be part of the primary analysis, and&#xD;
             therefore will not be required to meet the age criteria listed above. The older group&#xD;
             of donors will be chosen as the clinical discretion of the study investigators. No&#xD;
             specific ovarian reserve cutoffs will be required, although factors related to ovarian&#xD;
             reserve will be taken into consideration.&#xD;
&#xD;
        Major Exclusion Criteria for oocyte donors:&#xD;
&#xD;
          1. Under 18 years old&#xD;
&#xD;
          2. All patients who do not voluntarily give their written consent for participation.&#xD;
&#xD;
          3. Patients who do not meet standard institutional criteria for oocyte donation.&#xD;
&#xD;
          4. A diagnosis of polycystic ovarian syndrome (PCOS).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Reproductive Medicine Associates of New Jersey</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

